Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
The gene encoding the receptor-tyrosine kinase RET was first discovered more than three
decades ago, and activating RET rearrangements and mutations have since been identified …
decades ago, and activating RET rearrangements and mutations have since been identified …
State-of-the-Art Strategies for Targeting RET-Dependent Cancers
Activating receptor tyrosine kinase RET (rarranged during transfection) gene alterations
have been identified as oncogenic in multiple malignancies. RET gene rearrangements …
have been identified as oncogenic in multiple malignancies. RET gene rearrangements …
[HTML][HTML] Clinical and translational implications of RET rearrangements in non–small cell lung cancer
Since the discovery in 2012 of rearranged during transfection proto-oncogene gene (RET)
rearrangements in NSCLC, at least 12 different fusion variants have been identified, with …
rearrangements in NSCLC, at least 12 different fusion variants have been identified, with …
Targeting RET-rearranged non-small-cell lung cancer: future prospects
G Bronte, P Ulivi, A Verlicchi, P Cravero… - Lung Cancer: Targets …, 2019 - Taylor & Francis
Non-small-cell lung cancer (NSCLC) patients with mutated or rearranged oncogene drivers
can be treated with upfront selective inhibitors achieving higher response rates and longer …
can be treated with upfront selective inhibitors achieving higher response rates and longer …
Progresses Toward Precision Medicine in RET-altered Solid Tumors
RET (rearranged during transfection) gene encodes a receptor tyrosine kinase essential for
many physiologic functions, but RET aberrations are involved in many pathologies. While …
many physiologic functions, but RET aberrations are involved in many pathologies. While …
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies
M San Roman-Gil, J Pozas, D Rosero-Rodriguez… - Cancer treatment …, 2022 - Elsevier
Thyroid cancer is the most frequently diagnosed endocrine malignancy, with an increasing
incidence over the last decades. The recent advances in understanding the molecular …
incidence over the last decades. The recent advances in understanding the molecular …
[HTML][HTML] Chasing the target: new phenomena of resistance to novel selective RET inhibitors in lung cancer. Updated evidence and future perspectives
S Fancelli, E Caliman, F Mazzoni, M Brugia… - Cancers, 2021 - mdpi.com
Simple Summary REarranged during Transfection (RET) is an emerging target for several
types of cancer, including non-small cell lung cancer (NSCLC). The recent US FDA approval …
types of cancer, including non-small cell lung cancer (NSCLC). The recent US FDA approval …
[HTML][HTML] Cabozantinib for HCC treatment, from clinical back to experimental models
S Deng, A Solinas, DF Calvisi - Frontiers in oncology, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide. Patients with early-stage HCC can be treated successfully with surgical resection …
worldwide. Patients with early-stage HCC can be treated successfully with surgical resection …
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations
ZX Wang, QQ Li, J Cai, JZ Wu, JJ Wang… - Journal of Medicinal …, 2024 - ACS Publications
Over the past decades, the role of rearranged during transfection (RET) alterations in
tumorigenesis has been firmly established. RET kinase inhibition is an essential therapeutic …
tumorigenesis has been firmly established. RET kinase inhibition is an essential therapeutic …
[HTML][HTML] Progress in the management of advanced thoracic malignancies in 2017
R Ferrara, L Mezquita, B Besse - Journal of Thoracic Oncology, 2018 - Elsevier
The treatment paradigm of NSCLC underwent a major revolution during the course of 2017.
Immune checkpoint inhibitors (ICIs) brought remarkable improvements in response and …
Immune checkpoint inhibitors (ICIs) brought remarkable improvements in response and …